Evidence map›Paper›PMID 35164195›Full record

ArticleMolecules (Basel, Switzerland)2022

Development and Validation of a Novel HPLC Method to Analyse Metabolic Reaction Products Catalysed by the CYP3A2 Isoform: In Vitro Inhibition of CYP3A2 Enzyme Activity by Aspirin (Drugs Often Used Together in COVID-19 Treatment).

Amira Hussain, Declan P Naughton, James Barker

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amira HussainSchool of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-upon-Thames, London KT1 2EE, UK.
Declan P NaughtonSchool of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-upon-Thames, London KT1 2EE, UK.
James BarkerSchool of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-upon-Thames, London KT1 2EE, UK.ORCID 0000-0002-5863-9400
Kingston University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspirin (also known as acetylsalicylic acid) is a drug intended to treat fever, pain, or inflammation. Treatment of moderate to severe cases of COVID-19 using aspirin along with dexamethasone has gained major attention globally in recent times. Thus, the purpose of this study was to use High-Performance Liquid Chromatography (HPLC) to evaluate the in vitro inhibition of CYP3A2 enzyme activity using aspirin in rat liver microsomes (RLMs). In this study, an efficient and sensitive HPLC method was developed using a reversed phase C18 column (X Bridge 4.6 mm × 150 mm, 3.5 µm) at 243 nm using acetonitrile and water (70:30

Indexed as

AnimalsAspirinChromatography, High Pressure LiquidCOVID-19 Drug TreatmentCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDexamethasoneMaleMicrosomes, LiverPharmaceutical PreparationsProtein IsoformsRatsRats, Sprague-DawleyReproducibility of ResultsSARS-CoV-26-hydroxydexamethasoneAspirinCyp3a2 protein, ratCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDexamethasonePharmaceutical PreparationsProtein Isoforms6β-hydroxydexamethasoneaspirincompetitive inhibitorCYP3A activitycytochrome P450dexamethasone

Identifiers

PMID35164195
PMCPMC8838585
OpenAlexW4213244927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.